Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.75 USD | +2.52% | +7.33% | -28.58% |
May. 31 | Piper Sandler Starts Apellis Pharmaceuticals With Neutral Rating, $46 Price Target | MT |
May. 24 | Apellis Pharmaceuticals, Sobi Say Pegcetacoplan Reduces Post-Transplant Kidney Diseases | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.58% | 5.19B | |
-1.54% | 91.26B | |
-2.63% | 38.17B | |
-12.76% | 32.85B | |
+68.06% | 26.74B | |
-13.02% | 15.93B | |
-5.27% | 13.37B | |
-10.50% | 11.77B | |
-49.11% | 10.27B | |
+187.82% | 10.92B |
- Stock Market
- Equities
- APLS Stock
- News Apellis Pharmaceuticals, Inc.
- Transcript : Apellis Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08